The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021

Details

• Personal Author:
  Oliver, Sara E. ; Gargano, Julia W. ; Scobie, Heather ; Wallace, Megan ; Hadler, Stephen C. ; Leung, Jessica ; Blain, Amy E. ; McClung, Nancy ; Campos-Outcalt, Doug ; Morgan, Rebecca L. ; Mbaeyi, Sarah ; MacNeil, Jessica ; Romero, José R. ; Talbot, H. Keipp ; Lee, Grace M. ; Bell, Beth P. ; Dooling, Kathleen
• Corporate Authors:
  CDC COVID-19 Response Team. ; Centers for Disease Control and Prevention (U.S.). Epidemic Intelligence Service. ; University of Arizona. College of Medicine. ; McMaster University. Faculty of Health Sciences. Department of Health Research Methods, Evidence, and Impact. ; Vanderbilt University School of Medicine. ; Stanford University School of Medicine. ; University of Washington.
• Description:
  What is already known about this topic? On February 27, 2021, the Food and Drug Administration issued an Emergency Use Authorization (EUA) for the Janssen COVID-19 vaccine.
  
  What is added by this report? On February 28, 2021, after a transparent evidence-based review of all available data, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Janssen COVID-19 vaccine in persons aged ≥18 years for the prevention of COVID-19.
  
  What are the implications for public health practice? The Janssen COVID-19 vaccine has high efficacy against COVID-19–associated hospitalization and death. Persons may receive any ACIP-recommended COVID-19 vaccine and are encouraged to receive the earliest vaccine available to them. Use of all EUA-authorized COVID-19 vaccines is critical in controlling the pandemic.
  
  On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Janssen COVID-19 (Ad.26.COV2.S) vaccine (Janssen Biotech, Inc, a Janssen Pharmaceutical company, Johnson & Johnson; New Brunswick, New Jersey). The Janssen COVID-19 vaccine is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector vaccine, encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19 (1). Vaccination with the Janssen COVID-19 vaccine consists of a single dose (5 × 1010 virus particles per 0.5-mL dose) administered intramuscularly. On February 28, 2021, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation* for use of the Janssen COVID-19 vaccine in persons aged ≥18 years for the prevention of COVID-19. This vaccine is the third COVID-19 vaccine authorized under an EUA for the prevention of COVID-19 in the United States (2). To guide its deliberations regarding the vaccine, ACIP used the Evidence to Recommendations (EtR) framework,† following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.§ The ACIP recommendation for the use of the Janssen COVID-19 vaccine under an EUA is interim and will be updated as additional information becomes available.
  
  Suggested citation for this article: Oliver SE, Gargano JW, Scobie H, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021. MMWR Morb Mortal Wkly Rep. ePub: 2 March 2021.
  
  mm7009e4.htm?s_cid=mm7009e4_w
  
  mm7009e4-H.pdf
  
  
• Subjects:
  Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Viral Vaccines
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2021; v. 70 Early Release
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Name as Subject:
  Janssen COVID-19 vaccine
• Place as Subject:
  United States
• Pages in Document:
  4 pdf pages
• Volume:
  70
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:43d2a089d8cb5df4cb9cd34e5e70268308f495741a5ee36b1517824264edb2f0b0c7405fae9054ba802b52f3bf2cc819e95ac59bdd667bf870b722c3f3a9cdde
• Download URL:
  https://stacks.cdc.gov/view/cdc/103489/cdc_103489_DS1.pdf
• File Type:
  [PDF - 108.84 KB ]